In Brazil's pharmaceutical distribution market, the price a buyer pays for the same product from the same distributor varies based on factors that have nothing to do with the product itself. How large the buyer is, how often they order, how long they have been a customer, and whether they have a skilled buyer negotiating for them all affect the transaction price. This is not unique to pharmaceutical distribution, but the scale of the information asymmetry in this market makes the problem particularly sharp.
Understanding why this happens, and why it is structurally persistent, is useful for any independent pharmacy trying to make better purchasing decisions. This article examines the mechanics of pricing in Brazilian pharmaceutical distribution, where the information gaps are, and what closing those gaps actually means in practice.
How Distributor Pricing Works in Practice
Pharmaceutical distributors in Brazil operate within the CMED ceiling framework, which sets maximum prices for regulated medications. Below that ceiling, pricing is at the distributor's discretion. In practice, this means a distributor maintains a list price and a set of negotiated adjustments that vary by buyer.
Large buyers, primarily pharmacy chains buying in volume through centralized purchasing departments, negotiate framework agreements that set discounted prices for their order volumes. A chain buying 10,000 boxes of a generic statin per month across its network has substantial leverage. It can negotiate a price significantly below list, backed by the credible threat of switching to a competing distributor.
An independent pharmacy buying 50 boxes of the same product per month has far less leverage. It is not large enough to negotiate a framework agreement, and it typically does not have a dedicated buyer with the time and market knowledge to push for the best available price. It pays something close to list, or whatever the sales rep quoted in the most recent phone call, which may or may not reflect the most competitive offer available from that distributor at that moment.
The Role of Sales Rep Relationships
Distributor sales in Brazil's pharmaceutical sector are built on rep relationships. A rep assigned to a region maintains a portfolio of pharmacy accounts. They visit or call regularly, offer quotes on products, and sometimes have discretion to offer one-time deals to move slow-moving inventory or to win a pharmacy's business away from a competing distributor.
These relationships create real value for pharmacies that have them. A rep who knows your order patterns can alert you proactively when a product you buy regularly is going out of stock or going up in price. A rep with whom you have built trust over years may give you better terms during a shortage when supply is constrained.
But the relationship model also has a structural bias. The rep's time is finite. They prioritize the accounts that generate the most revenue or the most commission. A small pharmacy that orders infrequently is not a rep's top priority, which means it receives less proactive service and fewer one-time deal offers. The information flow is unequal: larger accounts learn about pricing opportunities faster and more reliably than small ones.
Fragmentation and Its Consequences
Brazil's pharmaceutical distribution market includes over 120 licensed national and regional distributors. For any given product, several distributors may carry it simultaneously, at somewhat different prices, with different delivery terms and different inventory levels. From the perspective of an independent pharmacy, this fragmentation is theoretically advantageous: there are many sellers to choose from. In practice, it is a disadvantage because the pharmacy lacks the information capacity to compare across all of them.
A pharmacy with three distributor relationships compares prices across three offers. A pharmacy with a single trusted distributor does not compare at all. Neither has visibility into what the other 100-plus distributors in the market are offering for the same product this week.
The result is a persistent information asymmetry that runs in favor of larger buyers. A chain pharmacy's centralized purchasing platform connects to many distributors and automatically surfaces the best available price for each product. An independent pharmacy's "platform" is the owner's memory of their last conversations with three reps.
What Price Transparency Means and What It Does Not
Price transparency in pharmaceutical distribution does not mean that every distributor publishes a public price list. That is unlikely to happen given the structural incentives: distributors price differently by buyer segment by design, and making those prices public would compress their ability to offer differentiated terms. It also would not suit the buyers who have negotiated better rates, since those rates becoming public would create pressure to extend them to all buyers.
What price transparency can mean in practice is making real prices visible to buyers within a contained marketplace. A platform that aggregates offers from multiple distributors and presents them to pharmacy buyers in a single interface is creating information visibility without requiring distributors to publish to the general public. The buyer sees more options. The distributor reaches buyers they would not have reached through their rep network. The information asymmetry narrows without requiring any party to publicly post their pricing.
This is the model Covalenty operates on. Distributors share pricing and availability through the platform in exchange for access to buyers. Pharmacies see offers from multiple distributors without having to make multiple phone calls. Neither side has to give up all pricing flexibility, but the gap between what an informed buyer can access and what an uninformed buyer ends up paying narrows.
The Limits of Transparency
We are not arguing that price transparency alone solves the structural disadvantages that independent pharmacies face relative to chain buyers. It does not. A chain pharmacy's pricing advantage comes not just from information but from volume, from centralized credit relationships with distributors, and from the leverage that comes with being a large-share buyer. An independent pharmacy using a price comparison platform still cannot match a chain's negotiating power.
What a transparency tool can do is narrow the gap by ensuring that an independent pharmacy is paying something closer to the best available market price rather than the first price offered. That is a meaningful improvement even if it does not eliminate the structural cost difference entirely. A 5 to 10 percent improvement on a pharmacy's monthly stock cost is real money, especially at margins where Brazilian independent pharmacies typically operate.
The longer-term argument for why transparency matters is about market health rather than just individual savings. A market where buyers have good information allocates product more efficiently, rewards distributors who are genuinely competitive rather than those who are simply better at relationship management, and creates pressure on pricing that ultimately benefits the pharmacies and, indirectly, the patients they serve. Better information is the precondition for a better-functioning market, not a substitute for competitive market structure.
What Independent Pharmacies Can Do Now
Before a marketplace platform reaches meaningful scale in a specific market, independent pharmacies can improve their position through several approaches that do not require a platform. Adding one or two new distributor relationships specifically to expand the comparison set is a straightforward starting point. Designating a specific time each ordering cycle for price comparison rather than making reactive purchasing decisions is operationally simple but often neglected. Tracking your own historical pricing by product and distributor in even a basic spreadsheet gives you a baseline to evaluate new quotes against.
None of these eliminate the information asymmetry, but they reduce it at low cost. A platform builds on this behavior by making it systematic and less time-intensive. The goal in both cases is the same: make sure that you are buying with more information rather than less.
